Background: Hospitalization-associated AKI is common and is associated with markedly increased mortality and morbidity. This prospective cohort study examined the feasibility and association of an AKI rehabilitation program with postdischarge outcomes. Methods: Adult patients hospitalized from September 1, 2019 to February 29, 2020 in a large health system in Pennsylvania with stage 2-3 AKI who were alive and not on dialysis or hospice at discharge were evaluated for enrollment. The intervention included patient education, case manager services, and expedited nephrology appointments starting within 1-3 weeks of discharge. We examined the association between AKI rehabilitation program participation and risks of rehospitalization or mortality in logistic regression analyses adjusting for comorbidities, discharge disposition, and sociodemographic and kidney parameters. Sensitivity analysis was performed using propensity score matching. Results: Among the high-risk patients with AKI who were evaluated, 77 of 183 were suitable for inclusion. Out of these, 52 (68%) patients were enrolled and compared with 400 contemporary, nonparticipant survivors of stage 2/3 AKI. Crude postdischarge rates of rehospitalization or death were lower for participants versus nonparticipants at 30 days (15% versus 34%; P=0.01) and at 90 days (31% versus 51%; P=0.01). After multivariable adjustment, participation in the AKI rehabilitation program was associated with lower risk of rehospitalization or mortality at 30 days (OR, 0.41; 95% CI, 0.16 to 0.93), with similar findings at 90 days (OR, 0.52; 95% CI, 0.25 to 1.05). Due to small sample size, propensity-matched analyses were limited. The participants' rehospitalization or mortality was numerically lower but not statistically significant at 30 days (18% versus 31%; P=0.22) or at 90 days (47% versus 58%; P=0.4). Conclusions: The AKI rehabilitation program was feasible and potentially associated with improved 30-day rehospitalization or mortality. Our interventions present a roadmap to improve enrollment in future randomized trials.
Background: Hospitalization-associated AKI is common and is associated with markedly increased mortality and morbidity. This prospective cohort study examined the feasibility and association of an AKI rehabilitation program with postdischarge outcomes. Methods: Adult patients hospitalized from September 1, 2019 to February 29, 2020 in a large health system in Pennsylvania with stage 2-3 AKI who were alive and not on dialysis or hospice at discharge were evaluated for enrollment. The intervention included patient education, case manager services, and expedited nephrology appointments starting within 1-3 weeks of discharge. We examined the association between AKI rehabilitation program participation and risks of rehospitalization or mortality in logistic regression analyses adjusting for comorbidities, discharge disposition, and sociodemographic and kidney parameters. Sensitivity analysis was performed using propensity score matching. Results: Among the high-risk patients with AKI who were evaluated, 77 of 183 were suitable for inclusion. Out of these, 52 (68%) patients were enrolled and compared with 400 contemporary, nonparticipant survivors of stage 2/3 AKI. Crude postdischarge rates of rehospitalization or death were lower for participants versus nonparticipants at 30 days (15% versus 34%; P=0.01) and at 90 days (31% versus 51%; P=0.01). After multivariable adjustment, participation in the AKI rehabilitation program was associated with lower risk of rehospitalization or mortality at 30 days (OR, 0.41; 95% CI, 0.16 to 0.93), with similar findings at 90 days (OR, 0.52; 95% CI, 0.25 to 1.05). Due to small sample size, propensity-matched analyses were limited. The participants' rehospitalization or mortality was numerically lower but not statistically significant at 30 days (18% versus 31%; P=0.22) or at 90 days (47% versus 58%; P=0.4). Conclusions: The AKI rehabilitation program was feasible and potentially associated with improved 30-day rehospitalization or mortality. Our interventions present a roadmap to improve enrollment in future randomized trials.
Authors: Yao Qiao; Jung-Im Shin; Yingying Sang; Lesley A Inker; Alex Secora; Shengyuan Luo; Josef Coresh; G Caleb Alexander; John W Jackson; Alex R Chang; Morgan E Grams Journal: Mayo Clin Proc Date: 2019-10-13 Impact factor: 7.616
Authors: Paul M Palevsky; Kathleen D Liu; Patrick D Brophy; Lakhmir S Chawla; Chirag R Parikh; Charuhas V Thakar; Ashita J Tolwani; Sushrut S Waikar; Steven D Weisbord Journal: Am J Kidney Dis Date: 2013-03-15 Impact factor: 8.860
Authors: Nihar R Desai; Joseph S Ross; Ji Young Kwon; Jeph Herrin; Kumar Dharmarajan; Susannah M Bernheim; Harlan M Krumholz; Leora I Horwitz Journal: JAMA Date: 2016-12-27 Impact factor: 56.272
Authors: Nicholas M Selby; Anna Casula; Laura Lamming; John Stoves; Yohan Samarasinghe; Andrew J Lewington; Russell Roberts; Nikunj Shah; Melanie Johnson; Natalie Jackson; Carol Jones; Erik Lenguerrand; Eileen McDonach; Richard J Fluck; Mohammed A Mohammed; Fergus J Caskey Journal: J Am Soc Nephrol Date: 2019-02-21 Impact factor: 10.121
Authors: Brian W Jack; Veerappa K Chetty; David Anthony; Jeffrey L Greenwald; Gail M Sanchez; Anna E Johnson; Shaula R Forsythe; Julie K O'Donnell; Michael K Paasche-Orlow; Christopher Manasseh; Stephen Martin; Larry Culpepper Journal: Ann Intern Med Date: 2009-02-03 Impact factor: 25.391
Authors: Jay L Xue; Frank Daniels; Robert A Star; Paul L Kimmel; Paul W Eggers; Bruce A Molitoris; Jonathan Himmelfarb; Allan J Collins Journal: J Am Soc Nephrol Date: 2006-02-22 Impact factor: 10.121
Authors: Samuel A Silver; Neill K Adhikari; Chaim M Bell; Christopher T Chan; Ziv Harel; Abhijat Kitchlu; Alejandro Meraz-Muñoz; Patrick A Norman; Adic Perez; Alireza Zahirieh; Ron Wald Journal: Clin J Am Soc Nephrol Date: 2021-05-21 Impact factor: 10.614
Authors: Victor Ortiz-Soriano; Joseph L Alcorn; Xilong Li; Madona Elias; Taha Ayach; B Peter Sawaya; Hartmut H Malluche; Ron Wald; Samuel A Silver; Javier A Neyra Journal: Can J Kidney Health Dis Date: 2019-02-21
Authors: Renske Wiersema; Ruben J Eck; Mikko Haapio; Jacqueline Koeze; Meri Poukkanen; Frederik Keus; Iwan C C van der Horst; Ville Pettilä; Suvi T Vaara Journal: BMC Nephrol Date: 2019-12-31 Impact factor: 2.388
Authors: Diana J Schreier; Andrew D Rule; Kianoush B Kashani; Kristin C Mara; Sandra L Kane-Gill; John C Lieske; Alanna M Chamberlain; Erin F Barreto Journal: Am J Nephrol Date: 2022-03-16 Impact factor: 4.605
Authors: Heather Personett May; Abby K Krauter; Dawn M Finnie; Rozalina Grubina McCoy; Kianoush B Kashani; Joan M Griffin; Erin F Barreto Journal: BMJ Open Date: 2022-06-22 Impact factor: 3.006